Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10515	Companies
221776	Keywords
150984	Articles
117326	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 07/02/2024 at 13:30, 1 year 11 months ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 1 year 11 months ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 1 year 11 months ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 1 year 11 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 1 year 11 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 1 year 11 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 1 year 11 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 1 year 11 months ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 1 year 11 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 1 year 11 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Accesswire

Published on 06/04/2026 at 18:25, 2 hours 44 minutes ago

Touchstone Exploration Inc. Proposed Fundraise of US$10 Million to US$15 Million
Published on 06/04/2026 at 14:45, 6 hours 24 minutes ago

Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026
Published on 06/04/2026 at 14:30, 6 hours 39 minutes ago

Predictiv AI's Shift Technologies Secures Multi-Phase Commercial Contract to Digitize and Scale Middle-Mile and Last-Mile Logistics for Prompt Xpress
Published on 06/04/2026 at 14:00, 7 hours 9 minutes ago

Horizon Aircraft Appoints Richard Alexander as Chief Engineer of Certified Programs
Published on 06/04/2026 at 14:00, 7 hours 9 minutes ago

GameSquare Issues Shareholder Letter Highlighting Strong Second Quarter and Year-to-Date Momentum

View all ACCESSWIRE

EQS Group

Published on 06/04/2026 at 20:00, 1 hour 8 minutes ago

Notes Reduction - Results of Consent Solicitation
Published on 06/04/2026 at 19:27, 1 hour 41 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/04/2026 at 18:30, 2 hours 38 minutes ago

FROM DUPLANTIS TO PALTRINIERI, FAIR PLAY MENARINI KICKS OFF ITS 30TH EDITION
Published on 06/04/2026 at 17:57, 3 hours 11 minutes ago

EQS-Adhoc: Viscom SE raises its forecast for incoming orders in the 2026 financial year following a major contract
Published on 06/04/2026 at 17:50, 3 hours 18 minutes ago

Monport Laser Showcases Engraving Opportunities in Germany Ahead of World Cup 2026

Les Echos

Published on 06/04/2026 at 20:00, 1 hour 9 minutes ago

Schneider Electric announces the reference share price the initial conversion/exchange ratio of its €850 million new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2034 and the results of the repurchase of the OC
Published on 06/04/2026 at 18:23, 2 hours 45 minutes ago

Shareholders’ Meeting and board of directors’ meeting held on June 4, 2026
Published on 06/04/2026 at 18:00, 3 hours 9 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of May 29, 2026
Published on 06/04/2026 at 17:45, 3 hours 24 minutes ago

Declaration of voting rights at the end of May 2026
Published on 06/04/2026 at 17:45, 3 hours 24 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE